Elan-J&J Deal Breaches Biogen Tysabri Deal: Court
By Erin Coe ( September 4, 2009, 4:20 PM EDT) -- A federal court has found that Ireland-based drug manufacturer Elan Corp. PLC violated a nine-year collaboration agreement with Biogen Idec Inc. for the development and marketing of multiple sclerosis medication Tysabri by entering into a separate $1 billion acquisition deal with a Johnson & Johnson affiliate....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.